ResistancetoHIVtherapy-EACSEuropeanAIDSClinical：抗HIV治疗的EACS欧洲艾滋病临床.pptVIP

下载本文档

12
0
约2.21万字
约 35页
2017-08-22 发布于重庆
举报
版权申诉

ResistancetoHIVtherapy-EACSEuropeanAIDSClinical：抗HIV治疗的EACS欧洲艾滋病临床.ppt

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

ResistancetoHIVtherapy-EACSEuropeanAIDSClinical：抗HIV治疗的EACS欧洲艾滋病临床.ppt

ITT analysis RAL arm: Integrase from 12/39 VFs = 4 RALR*; RT in 13/39 VFs = 5 FTCR EFV arm: RT from 9/45 VFs = 5 EFVR; 2 FTCR * NNRTI resistance mutations emerge rapidly in patients with detectable viraemia during NNRTI therapy Single NNRTI mutations can cause high-level NNRTI resistance and cross-resistance Resistance mutations continue to accumulate * * Viral rebound was most apparent in individuals who had more than one NRTI mutation at baseline. In contrast, the subset of patients with no NRTI mutations demonstrated a more durable viral load suppression of about 1.75 log10 copies/mL below baseline as of week 16. Those patients with four or more NRTI mutations at baseline showed virtually no response to etravirine. The number of NNRTI mutations also had an impact on etravirine efficacy, and there was transient suppression in some individuals who had just one NNRTI mutation at baseline. * * Pyrophosphate can also be an acceptor Antagonised by M184V, K65R, L74V * * * The clinical implications of these observations can be summarised as follows * The clinical implications of these observations can be summarised as follows * Ongoing Activity of ETV with a weak backboneStudy TMC125-C227: 2 NRTIs + ETV or PI Ruxrungtham, HIV Med 2008 ART-experienced, PI-naive patients with documented NNRTI resistance The genetic barrier of PIs in vitro De Meyer, Antimicrob Agents Chemother 2005; De Meyer, IHDRW 2006 Time (days) Increase in PI selection concentration 0 50 100 150 200 250 300 350 400 450 0 100 300 500 700 900 1100 DRV (R41T, K70E) RTV (G16E, M46I, V82F, I84V) SQV (G48V, A71V, G73S, I84V, L90M) NFV (L10F, D30N, R41K, K45I, M46I, V77I, I84V, N88D) APV (L10F, V32I, L33F, M46I, I47V, I50V) LPV (L10F, L23I, M46I, I50V, I54V, L63P, V82A) TPV (L33V, M46L, V82T) ATV (L10F, V32I, M46I, I62V, A71V, I84V, N88S) Emergence of PI mutation with DRV/r vs LPV/rTITAN study: OBR + DRV/r or LPV/r 1Johnson et al. Top HIV Med 2007; 0 10 20 30 Primary PI mutations1 NRTI RAMs1 VFs w